# US 2011/0033454 A1 · Methods For Treating Diseases Using Antibodies to Aminophospolipids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0033454 A1
- Document ID: US20110033454A1
- Status: Published application
- Kind: A1
- Application number: 12/869,283
- Filed: 2010-08-26
- Published: 2011-02-10
- Earliest claimed: 2002-07-15
- Assignees: Board of Regents, The University of Texas System
- Inventors: PHILIP E. THORPE; SOPHIA RAN
- Web page: https://patentgrep.com/patent/US20110033454A1

## CPC

- A61K 39/39533: {against materials from animals}
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6835: {the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/06: Antianaemics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2836: {against CD106}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- G01N 33/56983: {Viruses}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/77: Internalization into the cell
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A method of quantifying viral load in a biological sample, comprising contacting said biological sample with a first antibody, or an antigen-binding fragment thereof, in an amount effective to bind viruses in said biological sample and quantifying the bound viruses; wherein said first antibody binds to phosphatidylserine on the luminal surface of tumor vascular endothelial cells when administered to an animal with a solid tumor and wherein said first antibody exhibits significant binding to an ELISA plate coated with phosphatidylserine in an ELISA conducted in the presence of serum, but no detectable binding to an ELISA plate coated with phosphatidylcholine in an ELISA conducted in the presence of serum, wherein said ELISA conducted in the presence of serum comprises the steps of:
(a) coating a first ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate and coating a second ELISA plate with phosphatidylcholine to prepare a PC-coated ELISA plate;
(b) blocking said PS-coated ELISA plate and said PC-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said first antibody diluted in said blocking buffer to said PS-coated ELISA plate and said PC-coated ELISA plate under conditions effective to allow binding of said first antibody to said PS-coated ELISA plate and said PC-coated ELISA plate in the presence of serum; and
(d) detecting the binding of said first antibody to said PS-coated ELISA plate and said PC-coated ELISA plate in the presence of serum using a secondary antibody that binds to said first antibody; wherein said first antibody exhibits significant binding to said PS-coated ELISA plate, but no detectable binding to said PC-coated ELISA plate.

### Claim 33 (depends on 32)

The method of claim 32, wherein said first antibody effectively competes with the 3G4 antibody (monoclonal antibody 3G4 deposited as ATCC PTA 4545) in binding to an ELISA plate coated with phosphatidylserine in a competition ELISA conducted in the presence of serum, wherein said competition ELISA comprises:
(a) coating an ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate;
(b) blocking said PS-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said 3G4 antibody diluted in said blocking buffer to said PS-coated ELISA plate under conditions effective to allow binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum;
(d) detecting the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum using a secondary antibody that binds to said 3G4 antibody; and
(e) identifying a first antibody that effectively competes with said 3G4 antibody in said competition ELISA by selecting a first antibody that substantially reduces the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum.

### Claim 34 (depends on 32)

The method of claim 32, wherein said antibody is bound to a solid support.

### Claim 35 (depends on 32)

The method of claim 32, wherein said biological sample is a blood sample.

### Claim 36

A method of purging a virus from a biological sample, comprising contacting said biological sample with a first antibody, or an antigen-binding fragment thereof, in an amount effective to bind and remove said virus from said biological sample; wherein said first antibody binds to phosphatidylserine on the luminal surface of tumor vascular endothelial cells when administered to an animal with a solid tumor and wherein said first antibody exhibits significant binding to an ELISA plate coated with phosphatidylserine in an ELISA conducted in the presence of serum, but no detectable binding to an ELISA plate coated with phosphatidylcholine in an ELISA conducted in the presence of serum, wherein said ELISA conducted in the presence of serum comprises the steps of:
(a) coating a first ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate and coating a second ELISA plate with phosphatidylcholine to prepare a PC-coated ELISA plate;
(b) blocking said PS-coated ELISA plate and said PC-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said first antibody diluted in said blocking buffer to said PS-coated ELISA plate and said PC-coated ELISA plate under conditions effective to allow binding of said first antibody to said PS-coated ELISA plate and said PC-coated ELISA plate in the presence of serum; and
(d) detecting the binding of said first antibody to said PS-coated ELISA plate and said PC-coated ELISA plate in the presence of serum using a secondary antibody that binds to said first antibody; wherein said first antibody exhibits significant binding to said PS-coated ELISA plate, but no detectable binding to said PC-coated ELISA plate.

### Claim 37 (depends on 36)

The method of claim 36, wherein said first antibody effectively competes with the 3G4 antibody (monoclonal antibody 3G4 deposited as ATCC PTA 4545) in binding to an ELISA plate coated with phosphatidylserine in a competition ELISA conducted in the presence of serum, wherein said competition ELISA comprises:
(a) coating an ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate;
(b) blocking said PS-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said 3G4 antibody diluted in said blocking buffer to said PS-coated ELISA plate under conditions effective to allow binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum;
(d) detecting the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum using a secondary antibody that binds to said 3G4 antibody; and
(e) identifying a first antibody that effectively competes with said 3G4 antibody in said competition ELISA by selecting a first antibody that substantially reduces the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum.

### Claim 38 (depends on 36)

The method of claim 36, wherein said antibody is bound to a solid support.

### Claim 39 (depends on 38)

The method of claim 38, wherein said method is an affinity chromatography method.

### Claim 40 (depends on 36)

The method of claim 36, wherein said biological sample is a blood sample.

### Claim 41

A method for treating a mammal with septic shock, comprising administering to said mammal a pharmaceutical composition comprising a first antibody, or an antigen-binding fragment thereof, in an amount effective to treat said septic shock; wherein said first antibody effectively competes with the 3G4 antibody (monoclonal antibody 3G4 deposited as ATCC PTA 4545) in binding to an ELISA plate coated with phosphatidylserine in a competition ELISA conducted in the presence of serum, wherein said competition ELISA comprises:
(a) coating an ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate;
(b) blocking said PS-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said 3G4 antibody diluted in said blocking buffer to said PS-coated ELISA plate under conditions effective to allow binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum;
(d) detecting the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum using a secondary antibody that binds to said 3G4 antibody; and
(e) identifying a first antibody that effectively competes with said 3G4 antibody in said competition ELISA by selecting a first antibody that substantially reduces the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum.

### Claim 42 (depends on 41)

The method of claim 41, wherein said first antibody is a human, humanized, part-human, chimeric, recombinant or engineered antibody.

### Claim 43 (depends on 41)

The method of claim 41, wherein said antibody is an Fab dimer of said 3G4 antibody.

### Claim 44 (depends on 41)

The method of claim 41, wherein said mammal is a human patient.

### Claim 45

A method for treating a mammal with sickle cell anaemia, comprising administering to said mammal a pharmaceutical composition comprising a first antibody, or an antigen-binding fragment thereof, in an amount effective to treat said sickle cell anaemia; wherein said first antibody effectively competes with the 3G4 antibody (monoclonal antibody 3G4 deposited as ATCC PTA 4545) in binding to an ELISA plate coated with phosphatidylserine in a competition ELISA conducted in the presence of serum, wherein said competition ELISA comprises:
(a) coating an ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate;
(b) blocking said PS-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said 3G4 antibody diluted in said blocking buffer to said PS-coated ELISA plate under conditions effective to allow binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum;
(d) detecting the binding of said 304 antibody to said PS-coated ELISA plate in the presence of serum using a secondary antibody that binds to said 3G4 antibody; and
(e) identifying a first antibody that effectively competes with said 3G4 antibody in said competition ELISA by selecting a first antibody that substantially reduces the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum.

### Claim 46 (depends on 45)

The method of claim 45, wherein said first antibody is a human, humanized, part-human, chimeric, recombinant or engineered antibody.

### Claim 47 (depends on 45)

The method of claim 45, wherein said antibody is an Fab dimer of said 3G4 antibody.

### Claim 48 (depends on 45)

The method of claim 45, wherein said mammal is a human patient.

### Claim 49

A method for treating a mammal with a protozoan infection, comprising administering to said mammal a pharmaceutical composition comprising a first antibody, or an antigen-binding fragment thereof, in an amount effective to treat said protozoan infection; wherein said first antibody effectively competes with the 3G4 antibody (monoclonal antibody 3G4 deposited as ATCC PTA 4545) in binding to an ELISA plate coated with phosphatidylserine in a competition ELISA conducted in the presence of serum, wherein said competition ELISA comprises:
(a) coating an ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate;
(b) blocking said PS-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said 3G4 antibody diluted in said blocking buffer to said PS-coated ELISA plate under conditions effective to allow binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum;
(d) detecting the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum using a secondary antibody that binds to said 3G4 antibody; and
(e) identifying a first antibody that effectively competes with said 3G4 antibody in said competition ELISA by selecting a first antibody that substantially reduces the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum.

### Claim 50 (depends on 49)

The method of claim 49, wherein said first antibody is a human, humanized, part-human, chimeric, recombinant or engineered antibody.

### Claim 51 (depends on 49)

The method of claim 49, wherein said mammal is a human patient.

### Claim 52

A method for treating a mammal with antiphospholipid syndrome, comprising administering to said mammal a pharmaceutical composition comprising a first antibody, or an antigen-binding fragment thereof, in an amount effective to treat said antiphospholipid syndrome; wherein said first antibody effectively competes with the 3G4 antibody (monoclonal antibody 3G4 deposited as ATCC PTA 4545) in binding to an ELISA plate coated with phosphatidylserine in a competition ELISA conducted in the presence of serum, wherein said competition ELISA comprises:
(a) coating an ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate;
(b) blocking said PS-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said 3G4 antibody diluted in said blocking buffer to said PS-coated ELISA plate under conditions effective to allow binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum;
(d) detecting the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum using a secondary antibody that binds to said 3G4 antibody; and
(e) identifying a first antibody that effectively competes with said 3G4 antibody in said competition ELISA by selecting a first antibody that substantially reduces the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum.

### Claim 53 (depends on 52)

The method of claim 52, wherein said first antibody is a human, humanized, part-human, chimeric, recombinant or engineered antibody.

### Claim 54 (depends on 52)

The method of claim 52, wherein said mammal is a human patient.

### Claim 55

A method for competing with a pathogenic antibody from a patient with antiphospholipid syndrome for binding to its phospholipid-protein target, comprising contacting said pathogenic antibody bound to said phospholipid-protein target with a first antibody, or an antigen-binding fragment thereof, which displaces said pathogenic antibody from said phospholipid-protein target; wherein said phospholipid-protein target is a phosphatidylserine (PS)-β2-glycoprotein I target and wherein said first antibody effectively competes with the 3G4 antibody (monoclonal antibody 3G4 deposited as ATCC PTA 4545) in binding to an ELISA plate coated with phosphatidylserine in a competition ELISA conducted in the presence of serum, wherein said competition ELISA comprises:
(a) coating an ELISA plate with phosphatidylserine to prepare a PS-coated ELISA plate;
(b) blocking said PS-coated ELISA plate with a blocking buffer comprising 10% serum;
(c) adding said 3G4 antibody diluted in said blocking buffer to said PS-coated ELISA plate under conditions effective to allow binding of said 304 antibody to said PS-coated ELISA plate in the presence of serum;
(d) detecting the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum using a secondary antibody that binds to said 3G4 antibody; and
(e) identifying a first antibody that effectively competes with said 3G4 antibody in said competition ELISA by selecting a first antibody that substantially reduces the binding of said 3G4 antibody to said PS-coated ELISA plate in the presence of serum.

### Claim 56 (depends on 55)

The method of claim 55, wherein said first antibody is a human, humanized, part-human, chimeric, recombinant or engineered antibody.
